

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the Application of

Ernest Arenas, et al.

Application No.

09/980,913

Attorney Docket No.

0380-P02709US0

Filed:

May 21, 2002

For:

MATERIALS AND METHODS RELATING TO

NEURONAL DEVELOPMENT

Examiner:

Gerald G. Leffers Jr.

Group Art Unit:

1636

## **CERTIFICATE OF MAILING UNDER 37 C.F.R § 1.8(a)**

I hereby certify that this Correspondence is being deposited on the date identified below with the United States Postal Service as first-class mail in an envelope properly addressed to Mail Stop, COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Certificate

Lynn C. Fischer

Date of Certificate

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

In accordance with the provisions of 37 C.F.R. §1.56, Applicant hereby submits the attached Form PTO-1449 listing additional references which the Patent Examiner is requested to consider and make of record in the above-identified application. Copies of each of the listed references are enclosed herewith. This submission is believed to be in full compliance with the requirements of 37 CFR §§1.97 and 1.98.

In accordance with 37 C.F.R. §1.97(c), enclosed herewith is the required fee of \$180.00, as set forth in 37 C.F.R. §1.17(p).

In the opinion of the undersigned, the references submitted herewith, together with those previously submitted with the Information Disclosure Statement filed July 31, 2003 and the Supplemental Information Disclosure Statement filed January 15,

2004, are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

In the event that the fee required in connection with this submission is not enclosed, the Commissioner is authorized to charge such fee or credit any overpayment to the account of the undersigned attorneys, Account No. 04-1406. A Fee Transmittal sheet is enclosed in duplicate.

This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with MPEP §609.

Favorable consideration of this application is again respectfully requested.

Respectfully submitted,

DANN, DORFMAN, HERRELL & SKILLMAN A Professional Corporation Attorneys for Applicant(s)

Patrick J. Hagan

PTO Registration No. 27,643

Telephone: (215) 563-4100 Facsimile: (215) 563-4044 Enclosures - Form PTO-1449

Copies of references listed on PTO - 1449

185	
MN 16 200 TRANSMITTAL	Complete if known
	Application Number: 09/980,913
	Filing Date: May 21, 2002
	First Named Inventor: Ernest Arenas, et al.
	Title: Materials and Methods Relating to Neuronal Development
TOT. AMT. OF PAYMENT: $(1) + (2) + (3) = $180.00$	Our File No.: 0380-P02709US0

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)		
Authorization is hereby granted to charge payment of the following fees associated with this communication or credit any	3. ADDITIONAL FEES  Fee Description Fee Paid		
overpayment to Deposit Account 04-1406.			
X Any filing fees under 37 C.F.R. §1.16 for the presentation	Surcharge-late filing fee or oath  Surcharge - late provisional filing fee or cover sheet		
of extra claims.	Non-English specification		
Any patent application processing fees under 37 C.F.R.	For filing a request for reexamination		
§1.17	Requesting publication of SIR prior to Examiner action		
Any extensions of time that are required to maintain this application in a pending status, if not included herewith, are hereby requested.	Requesting publication of SIR after Examiner action		
Authorization is hereby granted to charge such extension fees to	Extension for response within first month		
Deposit Account No. 04-1406. Two copies of this transmittal are	Extension for response within second month		
enclosed for accounting purposes.	Extension for response within third month		
Payment enclosed: \$180.00	Extension for response within fourth month		
FEE CALCULATION	Notice of Appeal		
1. FILING FEE	Filing a brief in support of an appeal		
Fee Description Fee Paid	Request for oral hearing		
Utility filing fee	Petition to institute a public use proceeding  Petition to revive unavoidably abandoned application		
Design filing fee	Petition to revive unintentionally abandoned application		
	Issue fee		
Plant filing fee  Reissue filing fee	Advance Order (10 copies)		
	Publication Fee		
Provisional filing fee	Petitions to the Commissioner		
SUBTOTAL (1) \$0.00	Petitions related to provisional applications		
	Submission of Information Disclosure Stmt. 180.00		
	Recording each patent assignment per property (times number of properties)		
2. CLAIMS	Filing a submission after final rejection (37 CFR 1.129(a))		
Extra Fee Fee Paid	For each additional invention to be examined (37 CFR 1.129(b))		
Total Claims	Other fee (specify)		
Presented = = = = =			
Independent			
Claims  Presented - = 0 x =			
(b)			
Multiple Dependent Claim (first presentation) = 0			
(a) Enter 20 or number previously paid for (b) Enter 3 or number previously paid for			
SUBTOTAL (2) \$ 0.00	SUBTOTAL (3) \$ <u>180.00</u>		

Submitted	By:
Towns days	

Typed or
Printed Name Patrick J. Hagan Reg. Number 27,643

Signature Attack J. J.

Date November 12, 2004

Deposit Account User ID 04-1406

(85)	Complete if known		
FEE TRANSMITTAL	Application Number: 09/980,913		
	Filing Date: May 21, 2002		
	First Named Inventor: Ernest Arenas, et al.		
TRADEMAN.	Title: Materials and Methods Relating to Neuronal Development		
TOT. AMT. OF PAYMENT: (1) + (2) + (3) = \$ 180.00	Our File No.: 0380-P02709US0		

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)
Authorization is hereby granted to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 04-1406.  Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.	3. ADDITIONAL FEES  Fee Description  Surcharge-late filing fee or oath  Surcharge - late provisional filing fee or cover sheet
Any patent application processing fees under 37 C.F.R. §1.17  Any extensions of time that are required to maintain this application in a pending status, if not included herewith, are hereby requested. Authorization is hereby granted to charge such extension fees to Deposit Account No. 04-1406. Two copies of this transmittal are enclosed for accounting purposes.	Non-English specification  For filing a request for reexamination  Requesting publication of SIR prior to Examiner action  Requesting publication of SIR after Examiner action  Extension for response within first month  Extension for response within second month  Extension for response within third month  Extension for response within fourth month
Payment enclosed: \$180.00  FEE CALCULATION	Notice of Appeal
1. FILING FEE  Fee Description  Utility filing fee  Design filing fee  Plant filing fee  Reissue filing fee  Provisional filing fee  SUBTOTAL (1) \$ 0.00	Filing a brief in support of an appeal  Request for oral hearing  Petition to institute a public use proceeding  Petition to revive unavoidably abandoned application  Petition to revive unintentionally abandoned application  Issue fee  Advance Order (10 copies)  Publication Fee  Petitions to the Commissioner  Petitions related to provisional applications  Submission of Information Disclosure Stmt.  Recording each patent assignment per property  (times number of properties)
2. CLAIMS  Extra Fee Fee Paid  Total Claims  Presented = 0 x =  Independent Claims  Presented = 0 x =  (b)  Multiple Dependent Claim  (first presentation) = 0	(times number of properties)  Filing a submission after final rejection (37 CFR 1.129(a))  For each additional invention to be examined (37 CFR 1.129(b))  Other fee (specify)
(a) Enter 20 or number previously paid for (b) Enter 3 or number previously paid for  SUBTOTAL (2) \$ 0.00	SUBTOTAL (3) \$180.00

Submitted By:	
Typed or	


Printed Name Patrick J. Hagan Reg. Number 27,643

Date November 12, 2004

Deposit Account User ID

04-1406

Signature \_




UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1			

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1				

		OTHER PRIOR ART - NON-PATENT DOCUMENTS
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C4	Haque NS, LeBlanc CJ, Isacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant. 1997 May-Jun;6(3):239-48.
	C2	Åkerud P., Canals J., Snyder E.Y. and Arenas E. (2001) Neuroprotection through delivery of GDNF by neural stem cells in a mouse model of Parkinson's disease. Journal of Neuroscience, 21: 8108-8118.
	C3	Åkerud P., Holm P.C., Castelo-Branco G., Sousa K., Rodriguez FJ. and Arenas E. (2002) Persephin-overexpressing neural stem cells regulate the function of nigrostriatal dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Molecular and Cellular Neuroscience, 21: 205-222.
	C4	Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol. 2003 Oct;250 Suppl 3:III44-6.
	C5	Dunnett SB, Björklund A, Lindvall O. (2001) Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci. 2001, 2(5):365-9.
	C6	Von Bohlen und Halbach OB, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77.
	C7	Schwarz J. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr Opin Neurol. 2003 Dec;16 Suppl 1:S27-33.

EXAMINER'S	DATE
SIGNATURE	CONSIDERED



 Complete	if	known

Application Number: 09/980,913

Filing Date: May 21, 2002

First Named Inventor: Ernest Arenas, et al.

Group Art Unit:1636

Examiner Name: Gerald G. Leffers Jr.

SHEET Z OF 2

Attorney Docket Number: 0380-P02709US0

C8	Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003 May;9(5):589-95.
C9	Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290(5492): 767-773.
C10	Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2003 Jul;2(7):437-45.
C11	Wagner J., Åkerud P., Castro D., Holm P C., Canals J M., Snyder E Y., Perlmann T. and Arenas E. (1999). Induction of a Midbrain Dopaminergic Phenotype in Nurr1-Overexpressing Neural Stem Cells. Nature Biotechnology, 17: 653-659
C12	Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, Defer G, Samson Y, Peschanski M, Hantraye P, Cesaro P, Remy P. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov Disord. 2003 Aug;18(8):928-32.
C13	Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 2001 Aug;60(8):741-52.
C14	Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ. Related Articles, Links Abstract Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000 Nov;48(5):689-95.
C15	KIRIK, D., et al., "Localized striatal delivery of GDNF as a treatment for Parkinson disease", Nature Neuroscience, vol. 7: p. 105-110, (2004).

EXAMINER'S	DATE	
SIGNATURE	CONSIDERED	